New combo shows promise against tough lymphoma
NCT ID NCT03278782
First seen Jan 10, 2026 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study tests two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and romidepsin (which blocks enzymes cancer cells need to grow)—in people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to prior treatment. The goal is to see if the combination is safe and can shrink or control the cancer. About 39 adults are taking part, and the study is no longer recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.